MedTrace Logo

OssDsign® Spine Registry Study ("Propel")

NCT05329129 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-05-01

No results posted yet for this study

Summary

The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.

Conditions

  • Degenerative Disc Disease
  • Spinal Stenosis

Interventions

DEVICE

OssDsign® Catalyst

An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler

Sponsors & Collaborators

  • OssDsign

    lead INDUSTRY

Principal Investigators

  • Melanie Marshall · OssDsign

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2027-03-23
Completion
2027-04-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329129 on ClinicalTrials.gov